The molecular characterization of solid tumors such as glioblastoma and relapsed sarcoma has revealed a complex intra-tumoral heterogeneity that adapts quickly to standard-of-care (SOC) by activating “treatment response networks.” Dr. Pollok’s research program focuses on the development of novel multi-phase therapies that target primary and secondary treatment response networks. To evaluate mechanisms of action and efficacy, 3D cultures, patient-derived xenografts, and orthotopic modeling approaches are being utilized. Research areas include:

  • As a pipeline to discovery, use precision genomics and pharmacokinetic-pharmacodynamic approaches to understand adaptive response to treatment and identify biomarkers of response.

  • In adult and pediatric GBM, investigate a multi-phase approach that first targets two interconnected treatment response networks induced by SOC (Mdm2/p53/p73 and PI3K/Akt/mTOR), followed by a second phase of therapy targeting PI3K/Akt/mTOR and MAPK/ERK.

  • Discover novel maintenance and curative therapies for relapsed pediatric neuroblastoma and sarcomas (Ewings, osteosarcoma, and Rhabdomyosarcoma). Targets under investigation are EZH2, Chk1/2, and MYC.

Dr. Pollok's research interests include:

  • Modulation of DNA repair activity in hematopoietic stem and progenitor cells (HSPC) with a focus on in vivo models to study protection of HSC from chemotherapy
Past Affiliations
Oncology, Oncology, Pediatrics, Hematology
PhD, University of Kentucky, Medical Immunology, 1990
BS, College of William and Mary, Biology, 1983
gene therapy dna repair